$10.63
-0.19%Oaktree Acquisition Corp. III Life Sciences focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to acquire companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.
Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Positive working capital, but relatively tight. The company should monitor cash flow carefully.
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Conservative with tight liquidity: Low debt is positive, but current ratio warrants attention. Consider whether the company is efficiently deploying its equity capital.
OACC • NASDAQ
| Oaktree Acquisition Corp. III Life Sciences Balance Sheet | Dec 2025 | Dec 2024 |
|---|---|---|
ASSETS | ||
CURRENT ASSETS | ||
1.4M | 1.4M | |
1.4M | 1.4M | |
113.3K | 201.3K | |
1.5M | 1.6M | |
NON-CURRENT ASSETS | ||
201.6M | 193.6M | |
0.0 | 113.3K | |
201.6M | 193.7M | |
203.1M | 195.3M | |
LIABILITIES | ||
CURRENT LIABILITIES | ||
0.0 | 535.5K | |
11.8K | 11.8K | |
1.3M | 180K | |
1.3M | 727.3K | |
NON-CURRENT LIABILITIES | ||
7M | 7M | |
7M | 7M | |
8.3M | 7.7M | |
SHAREHOLDERS' EQUITY | ||
201.6M | 193.6M | |
-6.8M | -6.1M | |
194.8M | 187.5M | |
194.8M | 187.5M | |
SUMMARY | ||
203.1M | 195.3M | |
201.6M | 193.6M | |
11.8K | 11.8K | |
-1.4M | -1.3M | |
24,738,553 | 24,738,553 |
OACC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 29, 2025 | October 29, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 17, 2025 | October 17, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 12, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 06, 2025 | June 03, 2025 | 2025 | |
10-Q 10-Q 2025 Q1 Q1 | May 14, 2025 | March 31, 2025 | 2025 | |
10-K 10-K 2024 FY FY | March 27, 2025 | December 31, 2024 | 2024 | |
8-K 8-K 2025 N/A | January 07, 2025 | January 06, 2025 | 2025 |
Continue your OACC research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.